CN Patent

CN112779252B — 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸

Assigned to Capital Institute of Pediatrics · Expires 2023-05-26 · 3y expired

What this patent protects

本发明提出靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸，所述的反义寡核苷酸能够结合至SMN2基因启动子区的MeCP2富集的甲基化区域来促进脊髓性肌萎缩症患者细胞中SMN2基因的整体转录水平和SMN蛋白的表达水平，可以作为SMN靶向性治疗策略中的新治疗靶点。

USPTO Abstract

本发明提出靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸，所述的反义寡核苷酸能够结合至SMN2基因启动子区的MeCP2富集的甲基化区域来促进脊髓性肌萎缩症患者细胞中SMN2基因的整体转录水平和SMN蛋白的表达水平，可以作为SMN靶向性治疗策略中的新治疗靶点。

Drugs covered by this patent

Patent Metadata

Patent number
CN112779252B
Jurisdiction
CN
Classification
—
Expires
2023-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Capital Institute of Pediatrics
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.